<DOC>
	<DOC>NCT01062282</DOC>
	<brief_summary>The purpose of this study is to gain information on safety and efficacy from Korean patients who starting Ventavis treatment by observational method.</brief_summary>
	<brief_title>Hypertension Study of VentavisÂ® Inhalation Therapy in the Treatment of Patients With Pulmonary Arterial Hypertension (VENIS)</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Hypertension, Pulmonary</mesh_term>
	<mesh_term>Familial Primary Pulmonary Hypertension</mesh_term>
	<mesh_term>Iloprost</mesh_term>
	<criteria>The treating physician has chosen Ventavis as a suitable treatment for the patient Patient with PH and classified as NYHA functional class III or IV and WHO group 1 Any condition that prevents participation in the study, including pregnancy and other contraindications for Ventavis treatment (as listed in the current Ventavis patient package insert).</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2011</verification_date>
	<keyword>Pulmonary Hypertension</keyword>
</DOC>